Scheduled removal of Fiasp from the Pharmaceutical Benefits Scheme

JDRF Australia are aware that Fiasp insulin is currently scheduled for removal from the Pharmaceutical Benefits Scheme from 1 April 2023. If removed at this date, it will no longer be available at a subsidised cost however will reportedly be available privately for a period of time.  

This is a significant concern to us and for many thousands of Australians with type 1 diabetes (T1D) and other forms of insulin-dependent diabetes who use Fiasp as an important part of a well-established management regimen.  

There are several other insulins listed on the PBS, however, any changes to management routines will need to be made in consultation with healthcare professionals, and we are aware that such a change will be a source of substantial anxiety for many affected. 

JDRF have been actively following this issue up with both the manufacturer, Novo Nordisk, and the Government to ensure the deep concerns of our community are communicated and understood. 

Should you also wish to express your concerns directly, contact Novo Nordisk or the Department of Health.